HRP20210611T1 - Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala - Google Patents
Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala Download PDFInfo
- Publication number
- HRP20210611T1 HRP20210611T1 HRP20210611TT HRP20210611T HRP20210611T1 HR P20210611 T1 HRP20210611 T1 HR P20210611T1 HR P20210611T T HRP20210611T T HR P20210611TT HR P20210611 T HRP20210611 T HR P20210611T HR P20210611 T1 HRP20210611 T1 HR P20210611T1
- Authority
- HR
- Croatia
- Prior art keywords
- antibody
- protofibril
- stabilized
- monomer
- binds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22110509P | 2009-06-29 | 2009-06-29 | |
| PCT/IB2010/052947 WO2011001366A1 (en) | 2009-06-29 | 2010-06-29 | N-terminal truncated amyloid beta protofibrils/ oligomers for use in therapeutic and diagnostic methods for alzheimer's disease |
| EP10739701.0A EP2448968B1 (en) | 2009-06-29 | 2010-06-29 | ANTIBODIES SELECTIVE FOR N-TERMINALTRUNCATED AMYLOID-p PROTOFIBRILS/OLIGOMERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210611T1 true HRP20210611T1 (hr) | 2021-05-28 |
Family
ID=42832352
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210611TT HRP20210611T1 (hr) | 2009-06-29 | 2010-06-29 | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US20120100129A1 (enExample) |
| EP (2) | EP3892633A1 (enExample) |
| JP (3) | JP2012532094A (enExample) |
| AU (1) | AU2010267640B2 (enExample) |
| CA (1) | CA2765602C (enExample) |
| CY (1) | CY1124034T1 (enExample) |
| DK (1) | DK2448968T3 (enExample) |
| ES (1) | ES2864049T3 (enExample) |
| HR (1) | HRP20210611T1 (enExample) |
| HU (1) | HUE053949T2 (enExample) |
| LT (1) | LT2448968T (enExample) |
| PL (1) | PL2448968T3 (enExample) |
| PT (1) | PT2448968T (enExample) |
| SI (1) | SI2448968T1 (enExample) |
| SM (1) | SMT202100237T1 (enExample) |
| WO (1) | WO2011001366A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| PL2004688T5 (pl) | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania |
| NO2539366T3 (enExample) | 2010-02-26 | 2018-04-07 | ||
| AU2012228236B2 (en) * | 2011-03-16 | 2016-10-27 | Vivoryon Therapeutics N.V. | Diagnostic antibody assay |
| SMT202100263T1 (it) | 2014-07-10 | 2021-07-12 | Eisai R&D Man Co Ltd | Anticorpi leganti protofibrille a-beta migliorati |
| AU2016295650A1 (en) | 2015-07-21 | 2018-01-25 | Bioarctic Neuroscience Ab | Method for treatment of traumatic brain injury targeting aggregated peptides |
| MA45684A (fr) | 2016-07-14 | 2019-05-22 | Bioarctic Neuroscience Ab | Protéine d'apport du cerveau |
| JP7368856B2 (ja) | 2017-07-25 | 2023-10-25 | トゥルーバインディング，インコーポレイテッド | Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療 |
| US20210324056A1 (en) | 2018-07-24 | 2021-10-21 | Eisai R&D Management Co., Ltd. | Methods of treatment and prevention of alzheimer's disease |
| CN120058944A (zh) | 2019-01-30 | 2025-05-30 | 真和制药有限公司 | 抗gal3抗体及其用途 |
| WO2021006212A1 (ja) * | 2019-07-08 | 2021-01-14 | テルモ株式会社 | ハイブリドーマおよびその製造方法、並びにモノクローナル抗体およびその製造方法 |
| US12352719B2 (en) | 2019-09-20 | 2025-07-08 | KYCERA AVX Components Corporation | Somatic cell-based electrical biosensor |
| JP2023528797A (ja) | 2020-05-26 | 2023-07-06 | トゥルーバインディング，インコーポレイテッド | ガレクチン－３を遮断することにより炎症性疾患を処置する方法 |
| MD4172199T2 (ro) | 2020-06-26 | 2025-09-30 | Bioarctic Ab | Anticorpi care leagă protofibrila de alfa-sinucleină |
| US20250163135A1 (en) | 2021-07-09 | 2025-05-22 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| JP2024532438A (ja) | 2021-08-30 | 2024-09-05 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗Ａβプロトフィブリル抗体の皮下製剤及びその使用方法 |
| CA3243435A1 (en) | 2022-02-02 | 2023-08-10 | Eisai R&D Management Co., Ltd. | TREATMENT METHODS USING THE P-TAU181 LEVEL |
| IL321331A (en) | 2022-12-22 | 2025-08-01 | Bioarctic Ab | Antibody that binds to ABETAPE3 |
| US20250388664A1 (en) | 2024-06-20 | 2025-12-25 | Bioarctic Ab | Bispecific binding molecule |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5604102A (en) | 1992-04-15 | 1997-02-18 | Athena Neurosciences, Inc. | Methods of screening for β-amyloid peptide production inhibitors |
| DE60043165D1 (de) * | 1999-08-04 | 2009-11-26 | Univ Southern California | Globularer Aufbau vom Amyloid-beta- protein und deren Verwendungen |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| CA2487528A1 (en) * | 2002-07-24 | 2004-02-12 | Innogenetics N.V. | Prevention, treatment and diagnosis of diseases associated with beta-amyloid formation and/or aggregation |
| CN1942483B (zh) * | 2004-04-13 | 2012-09-26 | 弗·哈夫曼-拉罗切有限公司 | 抗p型选凝素抗体 |
| GB0413726D0 (en) * | 2004-06-18 | 2004-07-21 | Lauras As | Compounds |
| SE0401601D0 (sv) * | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| MX2007000998A (es) * | 2004-07-30 | 2007-07-11 | Rinat Neuroscience Corp | Anticuerpos dirigidos peptido beta-amiloide y procedimientos que usan los mismos. |
| PL2004688T5 (pl) * | 2006-03-23 | 2014-09-30 | Bioarctic Neuroscience Ab | Ulepszone przeciwciała wobec protofibryli oraz ich zastosowania |
| US8470321B2 (en) * | 2007-11-16 | 2013-06-25 | The Rockefeller University | Antibodies specific for the protofibril form of beta-amyloid protein |
| JP5747414B2 (ja) * | 2008-04-29 | 2015-07-15 | バイオアークティック ニューロサイエンス アーベー | α−シヌクレイン関連疾患についての治療および診断方法における使用のための抗体およびワクチン |
-
2010
- 2010-06-29 PL PL10739701T patent/PL2448968T3/pl unknown
- 2010-06-29 ES ES10739701T patent/ES2864049T3/es active Active
- 2010-06-29 US US13/379,523 patent/US20120100129A1/en not_active Abandoned
- 2010-06-29 EP EP21153326.0A patent/EP3892633A1/en active Pending
- 2010-06-29 JP JP2012516964A patent/JP2012532094A/ja not_active Withdrawn
- 2010-06-29 HR HRP20210611TT patent/HRP20210611T1/hr unknown
- 2010-06-29 HU HUE10739701A patent/HUE053949T2/hu unknown
- 2010-06-29 DK DK10739701.0T patent/DK2448968T3/da active
- 2010-06-29 PT PT107397010T patent/PT2448968T/pt unknown
- 2010-06-29 WO PCT/IB2010/052947 patent/WO2011001366A1/en not_active Ceased
- 2010-06-29 AU AU2010267640A patent/AU2010267640B2/en active Active
- 2010-06-29 LT LTEP10739701.0T patent/LT2448968T/lt unknown
- 2010-06-29 SI SI201032068T patent/SI2448968T1/sl unknown
- 2010-06-29 CA CA2765602A patent/CA2765602C/en active Active
- 2010-06-29 EP EP10739701.0A patent/EP2448968B1/en active Active
- 2010-06-29 SM SM20210237T patent/SMT202100237T1/it unknown
-
2017
- 2017-04-19 JP JP2017083057A patent/JP6884025B2/ja active Active
-
2019
- 2019-08-01 JP JP2019142344A patent/JP2019218362A/ja active Pending
-
2021
- 2021-04-27 CY CY20211100361T patent/CY1124034T1/el unknown
-
2022
- 2022-12-15 US US18/066,998 patent/US20230295283A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE053949T2 (hu) | 2021-08-30 |
| ES2864049T3 (es) | 2021-10-13 |
| US20230295283A1 (en) | 2023-09-21 |
| AU2010267640B2 (en) | 2015-03-05 |
| EP2448968B1 (en) | 2021-01-27 |
| PT2448968T (pt) | 2021-04-30 |
| CA2765602C (en) | 2021-05-25 |
| AU2010267640A1 (en) | 2012-01-19 |
| SI2448968T1 (sl) | 2021-07-30 |
| EP3892633A1 (en) | 2021-10-13 |
| PL2448968T3 (pl) | 2021-09-13 |
| CY1124034T1 (el) | 2022-05-27 |
| DK2448968T3 (da) | 2021-04-12 |
| US20120100129A1 (en) | 2012-04-26 |
| JP2012532094A (ja) | 2012-12-13 |
| EP2448968A1 (en) | 2012-05-09 |
| WO2011001366A1 (en) | 2011-01-06 |
| SMT202100237T1 (it) | 2021-05-07 |
| JP6884025B2 (ja) | 2021-06-09 |
| JP2019218362A (ja) | 2019-12-26 |
| JP2017197531A (ja) | 2017-11-02 |
| CA2765602A1 (en) | 2011-01-06 |
| LT2448968T (lt) | 2021-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210611T1 (hr) | Antitijela selektivna za amiloidne-beta-protofibrile/oligomere krnjih n-terminala | |
| Lord et al. | An amyloid-β protofibril-selective antibody prevents amyloid formation in a mouse model of Alzheimer's disease | |
| Pellenard et al. | High-precision U-Pb zircon ages for explosive volcanism calibrating the NW European continental Autunian stratotype | |
| Wang-Dietrich et al. | The amyloid-β oligomer count in cerebrospinal fluid is a biomarker for Alzheimer's disease | |
| JP5926368B2 (ja) | アミロイドペプチドを測定するための抗体、キットおよび方法 | |
| AR078650A1 (es) | Anticuerpo de union a il-1 beta | |
| JP2009525758A5 (enExample) | ||
| UA105768C2 (uk) | Антитіла до рецептора кінцевих продуктів глибокого глікування (rage) і їх застосування | |
| DE69940364D1 (de) | Fab Fragmentbibliotheken und Verfahren für deren Verwendung | |
| BRPI1015088A2 (pt) | peptídeo antigênio ou um fragmento funcional deste, composição farmacêutica, métodos para o tratamento de uma doença ou distúrbio neurodegenerativos tal como tauopatia, para induzir uma resposta imune em um animal, para diagnosticar uma doença, distúrbio ou condição e uma predisposição a doença, distúrbio ou condição, para monitorar a doença residual mínima em um paciente e para prever a receptividade de um paciente, anticorpo, kit de teste, epítopo e linha celular. | |
| WO2009006347A3 (en) | Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes | |
| BRPI0607486B8 (pt) | anticorpo humanizado l243 contra hla-dr presente nas células hladr+,composição farmacêutica, kit e uso dos referidos anticorpos. | |
| MX338640B (es) | Anticuerpo monoclonal anti-ligando difundible derivado de amiloide beta y usos de los mismos. | |
| JP2012532094A5 (enExample) | ||
| BRPI0812875A2 (pt) | " método pra identificar se ou não um indivíduo está sob risco de desenvolvimento de sépsis severa, anticorpo específico para proteína ligante de heparina, método pra reduzir o risco de um indivíduo desenvolver sépsis severa, e, kit de teste ". | |
| WO2007050359A8 (en) | Anti-addl monoclonal antibody and use thereof | |
| EP1886140A4 (en) | IMMUNOLOGICAL ASSAYS AND ANTIBODIES FOR ANTI-MÜLLERIAN HORMONE | |
| WO2014195728A3 (en) | Methods and compositions relating to neurodegenerative diseases | |
| MX2020010387A (es) | Metodos para detectar y cuantificar fgf21. | |
| MA34135B1 (fr) | Protéines de liaison à un antigène spécifiques pour un composant p de substance amyloïde sérique | |
| RU2017114626A (ru) | Антитело, связывающее линейный эпитоп человеческого р53, и его применение в диагностике | |
| JP2014223083A5 (enExample) | ||
| WO2018049053A3 (en) | Peptides and uses thereof for diagnosing and treating myasthenia gravis | |
| AR119268A1 (es) | Métodos de purificación de anticuerpos y composiciones de estos | |
| MX2023004212A (es) | Conjugados reactivos. |